All In Biotech

Drug Trial Radar · NCT06796517

Immunotherapy in Lymphoma

Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients

Last checked: Nov 20, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Jun 26, 2024

Primary completion

Dec 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Sung-Soo ParkAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Yeouido St. Mary's Hospital
First posted
Jan 28, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is: Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies? Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes. Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.

Conditions

  • Relapsed/refractory High Grade B Cell Lymphoma
  • High Grade B-cell Lymphoma
  • Diffuse Large B Cell Lymphoma Relapsed
  • Primary Mediastinal Large B-Cell Lymphoma
  • Burkitt Lymphoma

Interventions

  • CAR-T TherapyDrug

    It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.

  • Bispecific antibodyDrug

    It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.

  • Antibody-Drug ConjugateDrug

    It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.

  • Monoclonal antibodyDrug

    Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.

  • Proteasome InhibitorDrug

    It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.

  • IMiD treatmentDrug

    Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: From the start of treatment or the date of study enrollment until death from any cause, assessed up to 100 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul St. Mary Hospital

    Seoul, South Korea · Recruiting

  • Yeoido St. Mary Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.